Quantcast

Latest Polyclonal antibodies Stories

2014-10-22 04:22:27

PhosImmune and PureMHC Working Together On Immunotherapies for Cancer CHARLOTTESVILLE, Va. and AUSTIN, Texas, Oct. 22, 2014 /PRNewswire/ -- PhosImmune Inc. and PureMHC LLC today announced they have entered into a license and collaboration agreement to develop novel antibody-based immunotherapies designed to target cancers. PhosImmune possesses technology for the identification of phosphorylated peptides displayed on the surfaces of tumor cells in association with HLA molecules....

2014-10-14 12:29:20

PLYMOUTH, Minn., Oct. 14, 2014 /PRNewswire/ -- SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome. SilkTears, LLC has developed a naturally...

2014-10-14 08:33:06

-- CIAO!(TM) Technology Maximizes Selectivity of Conditionally Active Antibodies -- SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of Conditionally Active Biologics (CABs), today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,859,467, for its proprietary Comprehensive Integrated Antibody Optimization(TM) (CIAO!(TM)) technology platform. The BioAtla CIAO patent...

2014-07-02 08:26:14

BOCA RATON, Fla., July 2, 2014 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the addition of its newest plasma collection center located at 311 North Patterson Road, in Valdosta, Georgia. The almost 16,000 square foot state-of-the-art facility officially opened its doors for business on June 30(th) 2014 and brings the total number of BPC's plasma collection centers to sixteen. "This...

2014-06-18 23:16:14

Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Portland, Maine (PRWEB) June 18, 2014 Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding...

2014-06-04 12:29:22

ANNAPOLIS, Md., June 4, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax(®) anthrax vaccine program were recently presented at the 2014 U.S. Food and Drug Administration (FDA) Medical Countermeasures Initiative (MCMi) Regulatory Science Symposium in Silver Spring, MD. In a presentation entitled, "Recombinant Protective Antigen Vaccine (SparVax(®)) Provides Protection Equivalent to BioThrax(®) Against Lethal Challenge with Bacillus...

2014-06-04 08:29:36

MUMBAI and LA CHAUX-DE-FONDS, Switzerland, June 4, 2014 /PRNewswire/ -- - State-of-the-art Manufacturing Facility for Supply of Clinical Trial Material - With the Facility Glenmark has end-to-end Capabilities for the Development of Novel, State-of-the-art Monoclonal Antibodies Including Bi-specific Antibodies Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP...

2014-05-28 04:24:24

BREDA, The Netherlands, May 28, 2014 /PRNewswire/ -- arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X's SIMPLE Antibody(TM) technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to...

2014-05-23 04:20:53

LONDON, May 23, 2014 /PRNewswire/ -- New Company Created to be a Leading Provider of Technologies and Services to Enable Better Biopharmaceuticals - PolyTherics and Antitope to continue to trade as wholly owned subsidiaries of Abzena - New brand highlights depth and range of offering to the global biopharmaceutical industry - Abzena to establish headquarters in Cambridge, UK PolyTherics Limited ("PolyTherics"), a...

2014-04-30 08:33:09

Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues SAN DIEGO, April 30, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,709,755, its first patent directed to methods of generating conditionally active antibodies. Conditionally active antibodies are...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related